furosemide has been researched along with Gestational Hypertension in 4 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the maternal and neonatal efficacy and safety with furosemide, amlodipine or aspirin in women with mild/moderate chronic hypertension during pregnancy." | 9.19 | Management of chronic hypertension during pregnancy with furosemide, amlodipine or aspirin: a pilot clinical trial. ( Dominguez, L; Solis, A; Vigil-De Gracia, P, 2014) |
| "To determine the maternal and neonatal efficacy and safety with furosemide, amlodipine or aspirin in women with mild/moderate chronic hypertension during pregnancy." | 5.19 | Management of chronic hypertension during pregnancy with furosemide, amlodipine or aspirin: a pilot clinical trial. ( Dominguez, L; Solis, A; Vigil-De Gracia, P, 2014) |
| "To assess the pharmacodynamic effects of furosemide in pregnancy." | 3.74 | Maternal hemodynamic changes associated with furosemide treatment. ( Brateng, D; Carr, DB; Easterling, TR; Gavrila, D, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lopes Perdigao, J | 1 |
| Lewey, J | 1 |
| Hirshberg, A | 1 |
| Koelper, N | 1 |
| Srinivas, SK | 1 |
| Elovitz, MA | 1 |
| Levine, LD | 1 |
| Vigil-De Gracia, P | 1 |
| Dominguez, L | 1 |
| Solis, A | 1 |
| Carr, DB | 1 |
| Gavrila, D | 1 |
| Brateng, D | 1 |
| Easterling, TR | 1 |
| Gupta, N | 1 |
| Dalmia, S | 1 |
| Deka, D | 1 |
| Mittal, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Furosemide for Accelerated Recovery of Blood Pressure Postpartum[NCT03556761] | Phase 2 | 384 participants (Actual) | Interventional | 2018-06-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of subjects experiencing one or more adverse effects secondary to furosemide (NCT03556761)
Timeframe: 0-6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Furosemide | 0 |
| Placebo Oral Tablet | 1 |
Number of subjects that required additional hypertensive medication after discharge (NCT03556761)
Timeframe: 0 to 6 weeks post-partum
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Furosemide | 25 |
| Placebo Oral Tablet | 39 |
Number of women who had severe hypertension (systolic blood pressure>160 millimeters of mercury or diastolic blood pressure>110 millimeters of mercury) postpartum (NCT03556761)
Timeframe: 0-6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Furosemide | 81 |
| Placebo Oral Tablet | 86 |
To compare the rate of persistently elevated blood pressures (>140/90) in women that receive a five day furosemide course compared to those that receive placebo. (NCT03556761)
Timeframe: 0-7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Furosemide | 10 |
| Placebo Oral Tablet | 23 |
Number of days postpartum participants stayed in the hospital (NCT03556761)
Timeframe: 0-6 weeks postpartum
| Intervention | Days (Median) |
|---|---|
| Oral Furosemide | 2 |
| Placebo Oral Tablet | 2 |
Number of subjects with one or more readmission/ER visit that were hypertension related (NCT03556761)
Timeframe: 0-6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Furosemide | 9 |
| Placebo Oral Tablet | 16 |
Subjects with complications during hospitalization related to hypertensive disorders of pregnancy. (NCT03556761)
Timeframe: 0-6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Furosemide | 3 |
| Placebo Oral Tablet | 1 |
To compare the time (days) required to achieve a resolution of elevated blood pressure, adjusted for mode of delivery. (NCT03556761)
Timeframe: 0-14 days postpartum
| Intervention | days (Median) |
|---|---|
| Oral Furosemide | 10 |
| Placebo Oral Tablet | 10.5 |
2 trials available for furosemide and Gestational Hypertension
| Article | Year |
|---|---|
Furosemide for Accelerated Recovery of Blood Pressure Postpartum in women with a hypertensive disorder of pregnancy: A Randomized Controlled Trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Furosemide; Humans; Hypertension, Pregnancy- | 2021 |
Management of chronic hypertension during pregnancy with furosemide, amlodipine or aspirin: a pilot clinical trial.
Topics: Adult; Amlodipine; Antihypertensive Agents; Aspirin; Diuretics; Female; Furosemide; Humans; Hyperten | 2014 |
2 other studies available for furosemide and Gestational Hypertension
| Article | Year |
|---|---|
Maternal hemodynamic changes associated with furosemide treatment.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiac Output; Diuretics; Female; Follow- | 2007 |
Successful maternal and fetal outcome in a pregnancy with type V Takayasu's aortoarteritis.
Topics: Adult; Antihypertensive Agents; Arterial Occlusive Diseases; Calcium Channel Blockers; Diuretics; Fe | 2008 |